You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameNystatin
Accession NumberDB00646  (APRD01146)
TypeSmall Molecule
GroupsApproved, Vet Approved
DescriptionNystatin is a polyene antifungal drug to which many molds and yeasts are sensitive, including Candida spp. Nystatin has some toxicity associated with it when given intravenously, but it is not absorbed across intact skin or mucous membranes. It is considered a relatively safe drug for treating oral or gastrointestinal fungal infections.
Structure
Thumb
Synonyms
Mycostatin
Nistatina
NYS
Nystatin
Nystatine
Nystatinum
External IDs Not Available
Product Ingredients
IngredientUNIICASInChI KeyDetails
Nystatin dihydrateNot AvailableNot AvailableNot applicableDetails
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Dom-nystatin 100.000 Iu/ml Oral SuspensionSuspension100 unitOralDominion Pharmacal1998-08-05Not applicableCanada
Ftp-nystatinSolution / drops100000 unitOralFtp Pharmacal Inc.1998-10-092004-08-03Canada
Jamp-nystatin Oral Suspension USPSuspension100000 unitOralJamp Pharma Corporation2015-01-09Not applicableCanada
MestatinCream25000 unitVaginalMedic Laboratory LtÉe1980-12-311996-09-09Canada
Mycostatin Oral Suspension 100000iuLiquid100000 unitOralSquibb Canada Inc., Division Of Bristol Myers Squibb Canada Inc.1972-12-312003-07-28Canada
Mycostatin Oral Tab 500000iuTablet500000 unitOralSquibb Canada Inc., Division Of Bristol Myers Squibb Canada Inc.1955-12-312002-07-30Canada
Mycostatin Vaginal Crm 25000unitCream25000 unitVaginalSquibb Canada Inc., Division Of Bristol Myers Squibb Canada Inc.1973-12-312005-08-01Canada
Nadostine Sus 100000iu/mlSuspension100000 unitOralLab Nadeau LtÉe, Division Of Technilab Inc.1974-12-312004-08-03Canada
Nadostine Tab 100000unitTablet100000 unitVaginalLab Nadeau LtÉe, Division Of Technilab Inc.1973-12-312004-08-03Canada
Nadostine Tab 500000unitTablet500000 unitOralLab Nadeau LtÉe, Division Of Technilab Inc.1973-12-311999-09-28Canada
Nilstat 25000units/gCream25000 unitVaginalTechnilab Pharma Inc.1974-12-312004-08-03Canada
Nilstat Oral Dps 100000iu/mlSolution / drops100000 unitOralLederle Cyanamid Canada Inc.1970-12-311997-01-29Canada
Nilstat Orl Tab 500000unitTablet500000 unitOralLederle Cyanamid Canada Inc.1970-12-311997-01-29Canada
Nilstat Sucrose-freeSuspension100000 unitOralTechnilab Pharma Inc.1997-03-122004-08-03Canada
Nilstat Vag Crm 100000unit/gmCream100000 unitVaginalLederle Cyanamid Canada Inc.1973-12-311997-08-14Canada
Nilstat Vag Tab 100000unitTablet100000 unitVaginalLederle Cyanamid Canada Inc.1970-12-311997-08-14Canada
Nyaderm Oral Sus 100000unit/ml USPSuspension100000 unitOralTaro Pharmaceuticals, Inc.1989-12-31Not applicableCanada
Nyaderm Vag Crm 25000unit/gmCream25000 unitVaginalTaro Pharmaceuticals, Inc.1979-12-31Not applicableCanada
PHL-nystatin Suspension 100000 Unit/mlSuspension100000 unitOralPharmel IncNot applicableNot applicableCanada
PMS-nystatin Suspension 100000 Unit/mlSuspension100000 unitOralPharmascience Inc1989-12-31Not applicableCanada
Ratio-nystatinCream100000 unitVaginalTeva1998-10-14Not applicableCanada
Ratio-nystatinSolution / drops100000 unitOralTeva1996-09-12Not applicableCanada
Ratio-nystatinTablet100000 unitVaginalRatiopharm Inc Division Of Teva Canada Limited1998-07-092008-08-01Canada
Ratio-nystatinTablet500000 unitOralRatiopharm Inc Division Of Teva Canada Limited1997-01-202013-01-21Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
NyamycPowder100000 [USP'U]/gCutaneousUpsher Smith Laboratories2005-05-03Not applicableUs
Nyata Nystatin PowderKitTopicalCrown Laboratories2016-12-08Not applicableUs
NystatinCream100000 [USP'U]/gTopicalRemedy Repack2013-09-192016-12-30Us
NystatinCream100000 [USP'U]/gTopicalPhysicians Total Care, Inc.1995-01-31Not applicableUs
NystatinCream100000 [USP'U]/gTopicalA S Medication Solutions2006-05-31Not applicableUs
NystatinCream100000 [USP'U]/gTopicalPreferreed Pharmaceuticals Inc.2014-01-13Not applicableUs
NystatinSuspension100000 [USP'U]/mLOralPharmaceutical Associates, Inc.2009-06-01Not applicableUs
NystatinSuspension100000 [USP'U]/mLOralRebel Distributors2005-06-28Not applicableUs
NystatinSuspension100000 [USP'U]/mLOralRebel Distributors1995-04-15Not applicableUs
NystatinSuspension100000 [USP'U]/mLOralCardinal Health2009-06-01Not applicableUs
NystatinSuspension100000 [USP'U]/15mLOralLehigh Valley Technologies, Inc.2014-04-01Not applicableUs
NystatinTablet, film coated500000 [USP'U]/1OralSun Pharmaceutical Industries Limited1988-12-22Not applicableUs
NystatinTablet, coated500000 [USP'U]/1OralAvera Mc Kennan Hospital2016-03-21Not applicableUs
NystatinPowder100000 [USP'U]/gTopicalMayne Pharma2004-07-15Not applicableUs
NystatinSuspension100000 [USP'U]/mLOralPharmaceutical Associates, Inc.2016-02-01Not applicableUs
NystatinPowder100000 U/gTopicalGavis Pharmaceuticals, LLC.2014-09-26Not applicableUs
NystatinOintment100000 [USP'U]/gTopicalAidarex Pharmaceuticals LLC2002-09-03Not applicableUs
NystatinSuspension100000 [USP'U]/mLOralA S Medication Solutions1995-04-15Not applicableUs
NystatinSuspension100000 [USP'U]/mLOralPreferreed Pharmaceuticals Inc.2005-06-28Not applicableUs
NystatinOintment100000 [USP'U]/gTopicalE. Fougera & CO., A division of Fougera Pharmaceuticals Inc.1982-09-23Not applicableUs
NystatinSuspension100000 [USP'U]/mLOralQualitest2005-06-28Not applicableUs
NystatinCream100000 mg/gTopicalRebel Distributors1993-01-29Not applicableUs
NystatinSuspension100000 [USP'U]/mLOralPhysicians Total Care, Inc.1994-03-28Not applicableUs
NystatinOintment100000 [USP'U]/gTopicalRebel Distributors1982-09-23Not applicableUs
NystatinSuspension100000 [USP'U]/mLOralMorton Grove Pharmaceuticals, Inc.1995-04-15Not applicableUs
NystatinOintment100000 [USP'U]/gTopicalPerrigo New York Inc.2006-09-15Not applicableUs
NystatinSuspension100000 [USP'U]/mLOralVista Pharm, Inc.2012-05-01Not applicableUs
NystatinPowder100000 [USP'U]/gTopicalH.J. Harkins Company2009-09-15Not applicableUs
NystatinCream100000 [USP'U]/gTopicalLake Erie Medical Dba Quality Care Produts Llc2006-05-31Not applicableUs
NystatinSuspension100000 [USP'U]/mLOralA S Medication Solutions1988-02-29Not applicableUs
NystatinSuspension100000 [USP'U]/mLOralAtlantic Biologicals Corp.1995-04-15Not applicableUs
NystatinOintment100000 [USP'U]/gTopicalUnit Dose Services1982-09-23Not applicableUs
NystatinSuspension100000 [USP'U]/mLOralE. Fougera & CO., A division of Fougera Pharmaceuticals Inc.1984-06-07Not applicableUs
NystatinCream100000 [USP'U]/gTopicalQualitest2006-05-31Not applicableUs
NystatinTablet, coated500000 [USP'U]/1OralHeritage2011-10-31Not applicableUs
NystatinOintment100000 [USP'U]/gTopicalPhysicians Total Care, Inc.2007-04-11Not applicableUs
NystatinPowder100000 [USP'U]/gTopicalRebel Distributors2009-09-15Not applicableUs
NystatinCream100000 [USP'U]/gTopicalProficient Rx LP2010-07-21Not applicableUs
NystatinCream100000 [USP'U]/gTopicalPreferreed Pharmaceuticals Inc.2014-11-13Not applicableUs
NystatinCream100000 [USP'U]/gTopicalA S Medication Solutions2006-09-21Not applicableUs
NystatinSuspension100000 [USP'U]/mLOralVista Pharm, Inc.2010-05-10Not applicableUs
NystatinCream100000 [USP'U]/gTopicalCentral Texas Community Health Centers1979-02-01Not applicableUs
NystatinSuspension100000 [USP'U]/mLOralHi Tech Pharmacal Co., Inc.2012-01-27Not applicableUs
NystatinOintment100000 [USP'U]/gTopicalA S Medication Solutions2006-09-15Not applicableUs
NystatinSuspension100000 [USP'U]/mLOralA S Medication Solutions2005-06-28Not applicableUs
NystatinCream100000 [USP'U]/gTopicalProficient Rx LP1993-01-28Not applicableUs
NystatinCream100000 [USP'U]/gTopicalE. Fougera & CO., A division of Fougera Pharmaceuticals Inc.1979-02-01Not applicableUs
NystatinCream100000 [USP'U]/gTopicalArbor Pharmaceuticals1993-01-28Not applicableUs
NystatinPowder100000 [USP'U]/gTopicalPhysicians Total Care, Inc.2005-01-27Not applicableUs
NystatinSuspension100000 [USP'U]/mLOralRebel Distributors2012-01-27Not applicableUs
NystatinOintment100000 [USP'U]/gTopicalProficient Rx LP2002-09-03Not applicableUs
NystatinOintment100000 [USP'U]/gTopicalPreferreed Pharmaceuticals Inc.2014-02-10Not applicableUs
NystatinCream100000 [USP'U]/gTopicalA S Medication Solutions2006-09-21Not applicableUs
NystatinSuspension500000 [USP'U]/5mLOralPrecision Dose, Inc.2005-12-15Not applicableUs
NystatinTablet, film coated500000 [USP'U]/1OralTeva1990-09-30Not applicableUs
NystatinCream100000 [USP'U]/gTopicalTaro Pharmaceuticals U.S.A., Inc.1993-01-28Not applicableUs
NystatinCream100000 [USP'U]/gTopicalA S Medication Solutions2006-05-31Not applicableUs
NystatinOintment100000 [USP'U]/gTopicalA S Medication Solutions2006-09-15Not applicableUs
NystatinCream100000 [USP'U]/gTopicalPreferreed Pharmaceuticals Inc.2016-08-22Not applicableUs
NystatinCream100000 [USP'U]/gTopicalActavis Mid Atlantic LLC,2010-07-21Not applicableUs
NystatinPowder100000 U/gTopicalMajor2015-02-15Not applicableUs
NystatinTablet, film coated500000 [USP'U]/1OralAidarex Pharmaceuticals LLC1988-12-22Not applicableUs
NystatinSuspension100000 [USP'U]/mLOralCardinal Health2010-05-10Not applicableUs
NystatinTablet, film coated500000 [USP'U]/1OralAv Kare, Inc.2014-01-20Not applicableUs
NystatinSuspension100000 [USP'U]/mLOralbryant ranch prepack1995-04-15Not applicableUs
NystatinSuspension500000 [USP'U]/5mLOralCardinal Health2005-12-15Not applicableUs
NystatinTablet, film coated500000 [USP'U]/1OralCarilion Materials Management1990-09-30Not applicableUs
NystatinCream100000 [USP'U]/gTopicalGw Pharmaceuticals Ltd.2015-04-01Not applicableUs
NystatinSuspension100000 [USP'U]/mLOralTaro Pharmaceuticals U.S.A., Inc.1988-02-29Not applicableUs
NystatinCream100000 [USP'U]/gTopicalA S Medication Solutions2006-05-31Not applicableUs
NystatinCream100000 [USP'U]/gTopicalA S Medication Solutions2006-05-31Not applicableUs
NystatinSuspension100000 [USP'U]/mLOralPreferreed Pharmaceuticals Inc.2016-11-02Not applicableUs
NystatinOintment100000 [USP'U]/gTopicalActavis Mid Atlantic LLC,2002-09-03Not applicableUs
NystatinSuspension100000 [USP'U]/mLOralStat Rx USA2005-06-28Not applicableUs
NystatinPowder100000 [USP'U]/gTopicalX Gen Pharmaceuticals, Inc.2004-08-30Not applicableUs
NystatinTablet, film coated500000 [USP'U]/1OralCardinal Health1984-01-16Not applicableUs
NystatinPowder100000 [USP'U]/gTopicalVensun Pharmaceuticals, Inc.2014-09-01Not applicableUs
NystatinSuspension100000 [USP'U]/mLOralMc Kesson Packaging Services A Buisness Unit Of Mc Kesson Corporation1995-04-15Not applicableUs
NystatinCream100000 [USP'U]/gTopicalPerrigo New York Inc.2006-09-21Not applicableUs
NystatinSuspension100000 [USP'U]/mLOralA S Medication Solutions1988-02-29Not applicableUs
NystatinCream100000 [USP'U]/gTopicalDispensing Solutions, Inc.2006-05-31Not applicableUs
NystatinSuspension100000 [USP'U]/mLOralPharmaceutical Associates, Inc.2016-02-01Not applicableUs
NystopPowder100000 [USP'U]/gTopicalPaddock Laboratories, Inc.1996-08-16Not applicableUs
Approved Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Candistatin Topical Powder - 100000 Unit/gPowder100000 unitTopicalBristol Myers Squibb1996-12-312008-04-25Canada
Mycostatin Crm 100000unit/gmCream100000 unitTopicalSquibb Canada Inc., Division Of Bristol Myers Squibb Canada Inc.1970-12-312006-09-06Canada
Mycostatin Ont 100000iu/gmOintment100000 unitTopicalSquibb Canada Inc., Division Of Bristol Myers Squibb Canada Inc.1955-12-312002-07-30Canada
Mycostatin Topical Pwr 100,000units/gmPowder100000 unitTopicalConvatec, Division Of Bristol Myers Squibb Canada Co.1994-12-312008-11-12Canada
Nadostine Crm 100000iu/gmCream100000 unitTopicalLab Nadeau LtÉe, Division Of Technilab Inc.1974-12-312004-08-03Canada
Nadostine Ont 100000iu/gmOintment100000 unitTopicalLab Nadeau LtÉe, Division Of Technilab Inc.1974-12-312004-08-03Canada
Nilstat Top Crm 100000unit/gmCream100000 unitTopicalLederle Cyanamid Canada Inc.1979-12-311997-01-29Canada
Nilstat Top Ont 100000unit/gmOintment100000 unitTopicalLederle Cyanamid Canada Inc.1979-12-311997-01-29Canada
Nyaderm Crm 100000unit/gmCream100000 unitTopicalTaro Pharmaceuticals, Inc.1979-12-31Not applicableCanada
Nyaderm Ont 100000unit/gmOintment100000 unitTopicalTaro Pharmaceuticals, Inc.1979-12-31Not applicableCanada
Ratio-nystatinOintment100000 unitTopicalTeva1996-11-28Not applicableCanada
Ratio-nystatinCream100000 unitTopicalTeva1996-09-12Not applicableCanada
Unapproved/Other Products Not Available
International Brands
NameCompany
AdiclairArdeypharm
AfunginalEuro Generics
BiofanalPfleger
CandacideBe-Tabs Pharmaceuticals
CandermilLKM
CandexSquare
CandidiasFabra
CandistatAmbalal Sarabhai Enterprises
CandistinPharos
CanstatAspen Pharmacare
CazetinIfars
Diaper NZCheminter
DipniOmega
EnystinKalbe
FukangningDeyer
FungatinFerron
Fungicidin LecivaZentiva
FungistinBeximco
FungostatinNobel
FunistatinNobel
GynostatinIqfarma
KandistatinMetiska
KenalonTa Fong
LederlindRiemser
LedernystRiemser
LystinBiolab
MycostatinBristol Myers Squibb
NilstatGlenmark
NyadermTaro
NystanBristol Myers Squibb
Brand mixtures
NameLabellerIngredients
First Dukes Mouthwash CompoundingCutis Pharma, Inc.
First Marys Mouthwash CompoundingCutis Pharma, Inc.
FlagystatinAventis Pharma Ltd.
Flagystatin CreamSanofi Aventis
Flagystatin Vaginal OvuleSanofi Aventis
Kenacomb CreamWestwood Squibb, Division Of Bristol Myers Squibb Canada Inc.
Kenacomb Mild CreamWestwood Squibb, Division Of Bristol Myers Squibb Canada Inc.
Kenacomb Mild OintmentWestwood Squibb, Division Of Bristol Myers Squibb Canada Inc.
Kenacomb OintmentWestwood Squibb, Division Of Bristol Myers Squibb Canada Inc.
Kenacomb OntSquibb Canada Inc., Division Of Bristol Myers Squibb Canada Inc.
Lidecomb CreamMedicis Pharmaceutical Corporation
Mecomb Crm 0.1%Medic Laboratory LtÉe
NyataCrown Laboratories
Nystatin and TriamcinoloneSTAT RX LLC USA
Nystatin and Triamcinolone AcetonideE. Fougera & CO., A division of Fougera Pharmaceuticals Inc.
Ratio-triacombTeva
Theraderm CreamBimeda Mtc Animal Health Inc
Viaderm Kc CrmTaro Pharmaceuticals, Inc.
Viaderm Kc OntTaro Pharmaceuticals, Inc.
Categories
UNIIBDF1O1C72E
CAS number1400-61-9
WeightAverage: 926.0949
Monoisotopic: 925.503499979
Chemical FormulaC47H75NO17
InChI KeyZDFDJJJGIRGMBE-AFARJNEBSA-N
InChI
InChI=1S/C47H75NO17/c1-27-17-15-13-11-9-7-5-6-8-10-12-14-16-18-35(65-47-45(60)42(48)44(59)30(4)64-47)26-39(56)41(46(61)62)38(55)24-34(52)23-37(54)36(53)20-19-31(49)21-32(50)22-33(51)25-40(57)63-29(3)28(2)43(27)58/h5-6,8,10-18,27-33,35-39,41-45,47,49-51,53-56,58-60H,7,9,19-26,48H2,1-4H3,(H,61,62)/b6-5+,10-8+,13-11+,14-12+,17-15+,18-16+/t27?,28?,29?,30-,31?,32?,33?,35?,36?,37?,38?,39?,41?,42+,43?,44-,45+,47?/m1/s1
IUPAC Name
(21E,23E,25E,27E,31E,33E)-20-{[(3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy}-4,6,8,11,12,16,18,36-octahydroxy-35,37,38-trimethyl-2,14-dioxo-1-oxacyclooctatriaconta-21,23,25,27,31,33-hexaene-17-carboxylic acid
SMILES
C[[email protected]]1OC(OC2CC(O)C(C(O)CC(=O)CC(O)C(O)CCC(O)CC(O)CC(O)CC(=O)OC(C)C(C)C(O)C(C)\C=C\C=C\CC\C=C\C=C\C=C\C=C\2)C(O)=O)[C@@H](O)[C@@H](N)[C@@H]1O
Pharmacology
IndicationFor treatment of cutaneous or mucocutaneous mycotic infections caused by Candida species
Structured Indications
PharmacodynamicsNystatin is an antibiotic which is both fungistatic and fungicidal in vitro against a wide variety of yeasts and yeast-like fungi, including Candida albicans, C. parapsilosis, C. tropicalis, C. guilliermondi, C. pseudotropicalis, C. krusei, Torulopsis glabrata, Tricophyton rubrum, T. mentagrophytes. Nystatin acts by binding to sterols in the cell membrane of susceptible species resulting in a change in membrane permeability and the subsequent leakage of intracellular components. On repeated subculturing with increasing levels of nystatin, Candida albicans does not develop resistance to nystatin. Generally, resistance to nystatin does not develop during therapy. However, other species of Candida (C. tropicalis, C. guilliermondi, C. krusei, and C. stellatoides) become quite resistant on treatment with nystatin and simultaneously become cross resistant to amphotericin as well. This resistance is lost when the antibiotic is removed. Nystatin exhibits no appreciable activity against bacteria, protozoa, or viruses.
Mechanism of actionNystatin exerts its antifungal activity by binding to ergosterol found in fungal cell membranes. Binding to ergosterol causes the formation of pores in the membrane. Potassium and other cellular constituents leak from the pores causing cell death.
TargetKindPharmacological actionActionsOrganismUniProt ID
ErgosterolSmall moleculeyes
binder
Candida albicansnot applicabledetails
Related Articles
AbsorptionNystatin is not absorbed from intact skin or mucous membrane.
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Fungi
PathwaysNot Available
Pharmacogenomic Effects/ADRs Not Available
Interactions
Drug Interactions
DrugInteractionDrug group
AmlodipineThe risk or severity of adverse effects can be increased when Nystatin is combined with Amlodipine.Approved
Amphotericin BThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Nystatin.Approved, Investigational
AmrinoneThe risk or severity of adverse effects can be increased when Nystatin is combined with Amrinone.Approved
AzelnidipineThe risk or severity of adverse effects can be increased when Nystatin is combined with Azelnidipine.Approved
AzimilideThe risk or severity of adverse effects can be increased when Nystatin is combined with Azimilide.Investigational
BarnidipineThe risk or severity of adverse effects can be increased when Nystatin is combined with Barnidipine.Approved
BenidipineThe risk or severity of adverse effects can be increased when Nystatin is combined with Benidipine.Approved
BepridilThe risk or severity of adverse effects can be increased when Nystatin is combined with Bepridil.Approved, Withdrawn
BuspironeThe metabolism of Buspirone can be decreased when combined with Nystatin.Approved, Investigational
BusulfanThe serum concentration of Busulfan can be increased when it is combined with Nystatin.Approved, Investigational
CilnidipineThe risk or severity of adverse effects can be increased when Nystatin is combined with Cilnidipine.Approved
CinnarizineThe risk or severity of adverse effects can be increased when Nystatin is combined with Cinnarizine.Approved
CisaprideThe serum concentration of Cisapride can be increased when it is combined with Nystatin.Approved, Investigational, Withdrawn
ClevidipineThe risk or severity of adverse effects can be increased when Nystatin is combined with Clevidipine.Approved
ConivaptanThe metabolism of Conivaptan can be decreased when combined with Nystatin.Approved, Investigational
CyclosporineThe metabolism of Cyclosporine can be decreased when combined with Nystatin.Approved, Investigational, Vet Approved
DarodipineThe risk or severity of adverse effects can be increased when Nystatin is combined with Darodipine.Experimental
DidanosineDidanosine can cause a decrease in the absorption of Nystatin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DiltiazemThe risk or severity of adverse effects can be increased when Nystatin is combined with Diltiazem.Approved
DocetaxelThe metabolism of Docetaxel can be decreased when combined with Nystatin.Approved, Investigational
DofetilideThe metabolism of Dofetilide can be decreased when combined with Nystatin.Approved
EfonidipineThe risk or severity of adverse effects can be increased when Nystatin is combined with Efonidipine.Approved
EperisoneThe risk or severity of adverse effects can be increased when Nystatin is combined with Eperisone.Approved, Investigational
EtravirineThe serum concentration of Etravirine can be increased when it is combined with Nystatin.Approved
FelodipineThe risk or severity of adverse effects can be increased when Nystatin is combined with Felodipine.Approved, Investigational
FendilineThe risk or severity of adverse effects can be increased when Nystatin is combined with Fendiline.Withdrawn
FlunarizineThe risk or severity of adverse effects can be increased when Nystatin is combined with Flunarizine.Approved
FosphenytoinThe serum concentration of Nystatin can be decreased when it is combined with Fosphenytoin.Approved
GabapentinThe risk or severity of adverse effects can be increased when Nystatin is combined with Gabapentin.Approved, Investigational
IsradipineThe risk or severity of adverse effects can be increased when Nystatin is combined with Isradipine.Approved
LacidipineThe risk or severity of adverse effects can be increased when Nystatin is combined with Lacidipine.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Nystatin is combined with Lamotrigine.Approved, Investigational
LercanidipineThe risk or severity of adverse effects can be increased when Nystatin is combined with Lercanidipine.Approved, Investigational
LosartanThe metabolism of Losartan can be decreased when combined with Nystatin.Approved
Magnesium SulfateThe risk or severity of adverse effects can be increased when Nystatin is combined with Magnesium Sulfate.Approved, Vet Approved
ManidipineThe risk or severity of adverse effects can be increased when Nystatin is combined with Manidipine.Approved
MibefradilThe risk or severity of adverse effects can be increased when Nystatin is combined with Mibefradil.Withdrawn
NicardipineThe risk or severity of adverse effects can be increased when Nystatin is combined with Nicardipine.Approved
NifedipineThe risk or severity of adverse effects can be increased when Nystatin is combined with Nifedipine.Approved
NiguldipineThe risk or severity of adverse effects can be increased when Nystatin is combined with Niguldipine.Experimental
NiludipineThe risk or severity of adverse effects can be increased when Nystatin is combined with Niludipine.Experimental
NilvadipineThe risk or severity of adverse effects can be increased when Nystatin is combined with Nilvadipine.Approved
NimesulideThe risk or severity of adverse effects can be increased when Nystatin is combined with Nimesulide.Approved, Withdrawn
NimodipineThe risk or severity of adverse effects can be increased when Nystatin is combined with Nimodipine.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Nystatin is combined with Nisoldipine.Approved
NitrendipineThe risk or severity of adverse effects can be increased when Nystatin is combined with Nitrendipine.Approved
PerhexilineThe risk or severity of adverse effects can be increased when Nystatin is combined with Perhexiline.Approved
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Nystatin.Approved, Vet Approved
Picosulfuric acidThe therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Nystatin.Approved
PimozideNystatin may increase the arrhythmogenic activities of Pimozide.Approved
PinaveriumThe risk or severity of adverse effects can be increased when Nystatin is combined with Pinaverium.Approved
PregabalinThe risk or severity of adverse effects can be increased when Nystatin is combined with Pregabalin.Approved, Illicit, Investigational
PrenylamineThe risk or severity of adverse effects can be increased when Nystatin is combined with Prenylamine.Withdrawn
ProgesteroneThe therapeutic efficacy of Progesterone can be decreased when used in combination with Nystatin.Approved, Vet Approved
QuinidineThe metabolism of Quinidine can be decreased when combined with Nystatin.Approved
RanolazineThe metabolism of Ranolazine can be decreased when combined with Nystatin.Approved, Investigational
RifabutinThe serum concentration of Rifabutin can be increased when it is combined with Nystatin.Approved
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Nystatin.Approved
RifapentineThe serum concentration of Rifapentine can be increased when it is combined with Nystatin.Approved
RisedronateThe risk or severity of adverse effects can be increased when Nystatin is combined with Risedronate.Approved, Investigational
SolifenacinThe metabolism of Solifenacin can be decreased when combined with Nystatin.Approved
SucralfateSucralfate can cause a decrease in the absorption of Nystatin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SunitinibThe metabolism of Sunitinib can be decreased when combined with Nystatin.Approved, Investigational
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Nystatin.Approved, Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Nystatin is combined with Tolfenamic Acid.Approved
TranilastThe risk or severity of adverse effects can be increased when Nystatin is combined with Tranilast.Approved, Investigational
VerapamilThe risk or severity of adverse effects can be increased when Nystatin is combined with Verapamil.Approved
XylometazolineThe risk or severity of adverse effects can be increased when Nystatin is combined with Xylometazoline.Approved
ZiconotideThe risk or severity of adverse effects can be increased when Nystatin is combined with Ziconotide.Approved
ZolpidemThe serum concentration of Zolpidem can be increased when it is combined with Nystatin.Approved
Food Interactions
  • Take without regard to meals.
References
Synthesis ReferenceNot Available
General References
  1. Akaike N, Harata N: Nystatin perforated patch recording and its applications to analyses of intracellular mechanisms. Jpn J Physiol. 1994;44(5):433-73. [PubMed:7534361 ]
External Links
ATC CodesG01AA01A07AA02D01AA01G01AA51
AHFS Codes
  • 08:14.28
  • 84:04.08.28
PDB EntriesNot Available
FDA labelDownload (776 KB)
MSDSDownload (72.5 KB)
Clinical Trials
Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections2
1, 2CompletedTreatmentKidney Diseases / Transplantation, Kidney1
2CompletedTreatmentStomatitis, Denture1
2Unknown StatusTreatmentAnastomotic Leakage1
2, 3WithdrawnTreatmentMinor burns1
3CompletedSupportive CareChronic Myeloproliferative Disorders / Infection NOS / Leukemias / Lymphoma NOS / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes1
3CompletedTreatmentGastrointestinal Diseases / Oral Candidiasis / Vesicular Stomatitis1
3CompletedTreatmentHIV-1 Infections1
3CompletedTreatmentOral Candidiasis1
3Not Yet RecruitingPreventionCritical Illness / Sepsis / Shock, Septic / Ventilator Associated Pneumonia (VAP)1
4CompletedHealth Services ResearchKidney Failure,Chronic1
4CompletedPreventionCritical Illness / Fungal Prophylaxis / General Surgery / Prophylaxis of Candida Infections1
4CompletedPreventionVery Low Birth Weight Infants1
4CompletedTreatmentPhotochemotherapy Reaction1
4CompletedTreatmentVaginitis1
4Unknown StatusPreventionAnticandidal Property of Saccharomyces Boulardii on Very Low Birth Weight Infants1
Not AvailableCompletedPreventionOral Lichen Planus / Prophylaxis of Candida Infections1
Not AvailableCompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections1
Not AvailableCompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Oral Candidiasis3
Not AvailableUnknown StatusNot AvailableStomatitis, Denture1
Pharmacoeconomics
Manufacturers
  • Bayer pharmaceuticals corp
  • Bristol myers squibb co
  • Alpharma us pharmaceuticals division
  • Lederle laboratories div american cyanamid co
  • Actavis mid atlantic llc
  • Altana inc
  • Perrigo new york inc
  • Taro pharmaceuticals usa inc
  • Teva pharmaceuticals usa inc
  • Vintage pharmaceuticals llc
  • Westwood squibb pharmaceuticals inc
  • Bristol myers squibb
  • Barlan pharmacal co inc
  • Dava pharmaceuticals inc
  • Paddock laboratories inc
  • Coastal pharmaceuticals inc
  • Kv pharmaceutical co
  • Par pharmaceutical inc
  • Upsher smith laboratories inc
  • X gen pharmaceuticals inc
  • Warner chilcott co llc
  • Apothecon inc div bristol myers squibb
  • Glenmark generics inc usa
  • Bausch and lomb pharmaceuticals inc
  • E fougera div altana inc
  • Morton grove pharmaceuticals inc
  • Pharmaderm div altana inc
  • Pharmafair inc
  • Roxane laboratories inc
  • Vintage pharmaceuticals inc
  • Vistapharm inc
  • Wockhardt eu operations (swiss) ag
  • Savage laboratories inc div altana inc
  • Mutual pharmaceutical co inc
  • Quantum pharmics ltd
  • Sandoz inc
  • Usl pharma inc
  • Watson laboratories inc
  • Holland rantos co inc
  • Odyssey pharmaceuticals inc
Packagers
Dosage forms
FormRouteStrength
SuspensionOral100 unit
KitOral
CreamVaginal
SuppositoryVaginal
LiquidOral100000 unit
PowderTopical100000 unit
SuspensionOral100000 unit
TabletVaginal100000 unit
TabletOral500000 unit
CreamVaginal25000 unit
PowderCutaneous100000 [USP'U]/g
KitTopical
KitTopical
CreamTopical100000 mg/g
CreamTopical100000 [USP'U]/g
OintmentTopical100000 [USP'U]/g
PowderTopical100000 U/g
SuspensionOral100000 [USP'U]/mL
SuspensionOral100000 [USP'U]/15mL
SuspensionOral500000 [USP'U]/5mL
Tablet, coatedOral500000 [USP'U]/1
Tablet, film coatedOral500000 [USP'U]/1
CreamTopical
OintmentTopical
PowderTopical100000 [USP'U]/g
CreamTopical100000 unit
CreamVaginal100000 unit
OintmentTopical100000 unit
Solution / dropsOral100000 unit
Prices
Unit descriptionCostUnit
Nystatin 10 billion unit powder3014.1USD each
Nystatin 5 billion unit powder2096.1USD each
Nystatin 2 billion unit powder1116.9USD each
Nystatin 1 billion unit powder452.08USD each
Nystat-rx 5 billion unit powder447.0USD each
Nystatin 500 million unit powder130.75USD each
Pedi-Dri 100000 unit/gm Powder 56.7 gm Bottle105.87USD bottle
Nystatin 150mu Bottle94.5USD bottle
Nystatin 150 million unit powder42.25USD each
Nystatin 150000000 unit powder42.0USD each
Nystatin Nystatin Powder 50 Million unit Bottle39.99USD bottle
Mycostatin 100000 unit/gm Powder 15 gm Bottle36.99USD bottle
Nystop 100000 unit/gm Powder 15 gm Bottle29.99USD bottle
Nystatin 50 million unit powder19.75USD each
Nystatin 100000 unit/gm Ointment 15 gm Tube12.99USD tube
Nystatin 100000 unit/gm Cream 15 gm Tube6.5USD tube
Nystatin 100000 unit tablet5.29USD tablet
Nystatin vaginal tablet5.0USD tablet
Pedi-dri topical powder1.82USD g
Nystop 100000 unit/gm powder1.6USD g
Nystatin 500000 unit tablet0.71USD tablet
Nystatin 500000 unit oral tablet0.68USD tablet
Mycostatin 500000 unit orl tablet0.48USD tablet
Nystatin 100000 unit/ml Suspension0.25USD ml
Ratio-Nystatin 500000 unit Tablet0.25USD tablet
Nystatin 100000 unit/gm cream0.1USD g
Pms-Nystatin 100000 unit/ml Suspension0.05USD ml
Ratio-Nystatin 100000 unit/ml Suspension0.05USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point160 °C (decomposes)MSDS
water solubility360 mg/L (at 24 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP0.5Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.066 mg/mLALOGPS
logP-2.8ALOGPS
logP-2.7ChemAxon
logS-4.2ALOGPS
pKa (Strongest Acidic)3.62ChemAxon
pKa (Strongest Basic)9.11ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count17ChemAxon
Hydrogen Donor Count12ChemAxon
Polar Surface Area327.45 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity245.18 m3·mol-1ChemAxon
Polarizability102.11 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability0ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.8641
Blood Brain Barrier-0.9581
Caco-2 permeable-0.741
P-glycoprotein substrateSubstrate0.5182
P-glycoprotein inhibitor INon-inhibitor0.814
P-glycoprotein inhibitor IINon-inhibitor0.6721
Renal organic cation transporterNon-inhibitor0.96
CYP450 2C9 substrateNon-substrate0.8313
CYP450 2D6 substrateNon-substrate0.867
CYP450 3A4 substrateNon-substrate0.5273
CYP450 1A2 substrateNon-inhibitor0.916
CYP450 2C9 inhibitorNon-inhibitor0.9374
CYP450 2D6 inhibitorNon-inhibitor0.9354
CYP450 2C19 inhibitorNon-inhibitor0.9243
CYP450 3A4 inhibitorNon-inhibitor0.931
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.987
Ames testNon AMES toxic0.8992
CarcinogenicityNon-carcinogens0.9731
BiodegradationNot ready biodegradable0.8601
Rat acute toxicity2.1245 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9462
hERG inhibition (predictor II)Non-inhibitor0.8971
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
Taxonomy
DescriptionThis compound belongs to the class of chemical entities known as aminoglycosides. These are molecules or a portion of a molecule composed of amino-modified sugars.
KingdomChemical entities
Super ClassOrganic compounds
ClassOrganic oxygen compounds
Sub ClassOrganooxygen compounds
Direct ParentAminoglycosides
Alternative Parents
Substituents
  • Aminoglycoside core
  • Macrolide
  • Hexose monosaccharide
  • Glycosyl compound
  • O-glycosyl compound
  • Beta-hydroxy acid
  • Dicarboxylic acid or derivatives
  • Hydroxy acid
  • Monosaccharide
  • Oxane
  • 1,2-aminoalcohol
  • Amino acid or derivatives
  • Amino acid
  • Ketone
  • Lactone
  • Carboxylic acid ester
  • Secondary alcohol
  • Cyclic ketone
  • Carboxylic acid
  • Organoheterocyclic compound
  • Acetal
  • Carboxylic acid derivative
  • Oxacycle
  • Polyol
  • Organic nitrogen compound
  • Primary aliphatic amine
  • Organonitrogen compound
  • Carbonyl group
  • Primary amine
  • Hydrocarbon derivative
  • Organic oxide
  • Amine
  • Alcohol
  • Organopnictogen compound
  • Aliphatic heteromonocyclic compound
Molecular FrameworkAliphatic heteromonocyclic compounds
External Descriptors

Targets

1. Ergosterol
Kind
Small molecule
Organism
Candida albicans
Pharmacological action
yes
Actions
binder
References
  1. Silva L, Coutinho A, Fedorov A, Prieto M: Competitive binding of cholesterol and ergosterol to the polyene antibiotic nystatin. A fluorescence study. Biophys J. 2006 May 15;90(10):3625-31. Epub 2006 Feb 24. [PubMed:16500971 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 10, 2016 12:53